Company intelligence / Profile preview
Apexian Pharmaceuticals
Indianapolis, Indiana, United Stateszoominfo.com ↗
- Ownership
- Private
- Employees
- ~4
- Development stage
- Phase 2
01
Overview
APX3330 has completed Phase 2 trials for Diabetic Retinopathy/Diabetic Macular Edema with Ocuphire Pharma. It has been dosed twice-a-day in over 400 subjects across 11 Phase 1 and Phase 2 trials, with few systemic adverse events reported and clinical data supporting chronic administration[6][8].
- Therapeutic areas
- OphthalmologyOncologyGastroenterology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Ocuphire Pharma
Beyond the preview
Go deeper on Apexian Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apexian Pharmaceuticals.